Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health (NYSE: ELAN) has joined the Greener Cattle Initiative, committing approximately $5 million over five years to fund research aimed at reducing methane emissions in beef and dairy production. This effort, led by the Foundation for Food & Agriculture Research, responds to the urgent need for climate action as highlighted by the UN. Elanco's participation aligns with its sustainability goals, including its pledge to remove 21 million tons of emissions from customer farms by 2030.
Elanco Animal Health reported a 27% increase in third quarter revenue, reaching $1,131 million, boosted by the Bayer Animal Health acquisition. The company updated its full-year revenue guidance to $4,730 to $4,770 million while maintaining adjusted EPS guidance of $0.97 to $1.03. However, reported EPS was $(0.21). Gross margin improved significantly to 55.6%. Elanco's operational performance reflected strong fundamentals, particularly in the Farm Animal and Pet Health sectors, with significant product contributions. The company anticipates continued growth in 2022.
Elanco Animal Health (NYSE: ELAN) has been recognized in FORTUNE’s 2021 Change the World list, ranking 19th among 53 companies making a social or environmental impact. This accolade highlights Elanco's East Africa Growth Accelerator (EAGA), which supports smallholder farmers in Tanzania, Kenya, and Uganda by providing affordable veterinary products and training. The initiative, begun in 2017 with backing from the Bill & Melinda Gates Foundation, integrates into Elanco's operations, emphasizing animal health's role in addressing hunger and climate challenges.
Elanco Animal Health (NYSE: ELAN) is set to announce its third quarter 2021 financial results on November 5, 2021. A conference call will follow at 8:00 a.m. eastern time to discuss the company's performance, accessible via a live webcast on Elanco's website. The company specializes in products and services aimed at preventing and treating diseases in farm animals and pets, emphasizing sustainability and community impact. With nearly 70 years of experience in animal health, Elanco aims to improve the welfare of animals globally.
Elanco Animal Health (NYSE: ELAN) announces the appointment of Ellen de Brabander, Ph.D., as the new executive vice president of Innovation and Regulatory Affairs, effective October 18. She brings extensive experience, including leading the development of NexGard. The company maintains its innovation revenue expectations of $600 to $700 million by 2025, driven by the acquisition of KindredBio and ongoing pipeline advancements. Additionally, Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform to establish an independent biopharmaceutical entity.
Summary not available.
Summary not available.
Summary not available.
Elanco Animal Health has completed the acquisition of Kindred Biosciences for
Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. CEO Jeff Simmons will join a virtual fireside chat at 3:30 p.m. ET. Investors can access a live audio webcast on Elanco's investor website, with a replay available for 90 days.
Elanco is a leader in animal health, focusing on innovative solutions for the well-being of farm animals and pets. With nearly 70 years of experience, they aim to enhance animal health and contribute positively to communities worldwide.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
